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Timely reperfusion therapy by primary percutaneous coronary intervention 
(PPCI) combined with effective secondary preventative therapy, have 
contributed to a decline in mortality rates following ST-segment elevation 
myocardial infarction (STEMI) over the last few years. However, the incidence 
and severity of heart failure following STEMI is rising. As such, novel 
cardioprotective therapies are required to reduce myocardial infarct (MI) size 
and preserve left ventricular (LV) systolic function, in order to prevent heart 
failure and improve clinical outcomes following PPCI1,2.  
 Over recent years, a large number of cardioprotective therapies, which 
have been demonstrated to be effective at reducing MI size in the laboratory 
setting, have been unable to either reduce MI size or improve clinical outcomes 
following STEMI. The reasons for this are manifold, and have been discussed 
extensively in the recent literature1-3. In summary, the failure to translate 
cardioprotection for patient benefit has been attributed to several key factors: 
the inadequacy of the animal models used for testing novel cardioprotective 
therapies in the laboratory setting; a failure to demonstrate consistent and 
robust cardioprotection in experimental studies before proceeding to clinical 
studies; and poorly designed clinical cardioprotection studies1-3.    
Another major reason for the failure to translate cardioprotection, may 
have been due to the adoption of a single-targeted mono-therapy approach, a 
strategy which may be inadequate to address the multi-faceted components of 
myocardial reperfusion injury – these include endothelial dysfunction, 
microvascular obstruction, oxidative stress, calcium overload, mitochondrial 
dysfunction, and inflammation2,4. In order to address this issue, an emerging 
concept in the cardioprotection field has been to adopt a multi-targeted strategy 
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using two or more therapies in combination to reduce MI size following 
STEMI1,2,5-7. The adoption of combination therapy as a multi-targeted 
cardioprotective strategy may be mediated as follows: (1) using two or more 
therapies to target different cardioprotective intracellular signaling pathways 
within the cardiomyocyte5,7; (2) using two or more therapies to target 
cardioprotection in different cell components within the heart such as 
endothelial cells, platelets, cardiomyocytes, and inflammatory cells; and (3) 
using one therapy with capabilities of reducing MI size through two or more 
cardioprotective targets such as inflammatory cells and cardiomyocytes.  
In this regard, the NACIAM study by Pasupathy et al8, in this issue of 
Circulation, investigated the MI-limiting effects of combining 2 ‘old’ 
cardioprotective therapies, N-acetylcysteine (NAC, anti-oxidant) and 
Nitroglycerin (NTG, a nitric oxide donor)9, in STEMI patients treated by PPCI. 
In a multi-center study of 112 STEMI patients, they found that the administration 
of a 48-hour intravenous (IV) infusion of NAC, initiated prior to PPCI, on a 
background of a low dose 48-hour IV NTG infusion, reduced acute MI size by 
over 30% in a subset of 75 patients (quantified by late gadolinium enhancement 
cardiovascular magnetic resonance, CMR). Importantly, the MI-limiting effect 
of NAC was still present at 3 months post-PPCI, with a 50% reduction in chronic 
MI size when compared to placebo, suggesting a long-term cardioprotective 
effect with this therapeutic approach.  
Interestingly the concept of combining NTG and NAC was first tested 
nearly 30 years ago in unstable angina patients, and was shown to reduce the 
incidence of acute myocardial infarction and was based on the premise that 
NAC may augment the anti-platelet and vasodilatory effects of NTG, although 
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significant hypotension resulted from this combination10. However, the 
combination had not been tested on MI size in STEMI patients, and importantly, 
the combination of NAC and NTG did not cause symptomatic hypotension in 
the NACIAM trial8.   
Previous experience with anti-oxidant therapies to target myocardial 
reperfusion injury have been largely disappointing with NAC failing to reduce 
MI size in experimental studies11 and trimetazidine having no beneficial effects 
following STEMI12. The failure of anti-oxidant therapy as a cardioprotective 
strategy has been attributed to the inability to effectively scavenge reactive 
oxygen species, especially at the level of mitochondria. As such, the use of a 
relatively high dose of NAC (29g over 48 hours) in the NACIAM trial, may, in 
part, have overcome this limitation of anti-oxidant therapy.   
The authors are to be congratulated for demonstrating a cardioprotective 
effect with the anti-oxidant, NAC, in STEMI patients on a background of low-
dose NTG.  However, there are several issues to be discussed concerning the 
trial design of the NACIAM trial. First, is the lack of factorial design for testing 
the cardioprotective effects of NAC and NTG, separately, and in combination – 
this would have allowed the authors to ascertain whether the combination of 
NAC and NTG is more effective at reducing MI size in STEMI patients, when 
compared to either agent given alone. Given that it is not routine clinical practice 
to give low-dose IV NTG for 48 hours to reperfused STEMI patients, it is not 
clear why this was adopted as background therapy for the NACIAM trial. The 
factorial design would have also provided additional information on whether IV 
NTG per se can limit MI size in the STEMI setting. Nitric oxide (NO) is a well-
known mediator of cardioprotection, and NO donors have been shown to limit 
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MI size in experimental animal models. However, the use of intracoronary 
nitrite13 and inhaled nitric oxide (NOMI trial NCT01398384) as adjuvants to 
PPCI, have all failed to reduce MI size following STEMI, although this may 
relate to patient selection (post-hoc subgroup analysis showed benefit in 
STEMI patients presenting with an occluded coronary artery)13, and prior 
administration of sublingual nitrates (NOMI trial NCT01398384).  
 Secondly, the wide range of timing of the initial CMR scan in the NACIAM 
trial of 3 to 7 days post-PPCI, may have impacted on detection of the edema-
based area-at-risk (AAR), microvascular obstruction, and MI size, given that 
recent data have suggested that these CMR variables are dynamic in nature 
over the first week following PPCI14. Under ideal circumstances the acute CMR 
scan should be performed between 3 to 5 days following STEMI, when these 
variables are at their peak15,  However, it is appreciated that timing the initial 
CMR scan to particular days can be logistically challenging in the first few days 
following STEMI. Moreover, the use of different CMR vendors (Philip and 
Siemens) within the NACIAM trial, may also have impacted on the 
quantification of the AAR by T2-weighted CMR and MI size by CMR. 
Finally, the authors demonstrated impressive reductions in MI size (30-
50%) with NAC treatment on the initial and follow-up CMR scans, and yet, there 
were no beneficial effects on post-MI left ventricular (LV) remodeling with no 
change in either LV dimensions or ejection fraction at 3 months. The reason for 
the discrepancy, is unclear, and further studies are required to investigate the 
impact of NAC treatment on parameters of post-MI LV remodeling, and whether 
it can improve clinical outcomes following STEMI.  
6 
 
 In summary, the NACIAM study by Pasupathy et al8, marks a step in the 
right direction for the field of cardioprotection, as it highlights the therapeutic 
potential of combining two different cardioprotective therapies to reduce MI size 
following STEMI. However, further studies are required to elucidate the 
individual contributions of NAC and NTG to the cardioprotective effects 
observed in the NACIAM study, and to also investigate the effects of NAC on 
post-MI LV remodeling and clinical outcomes following PPCI.   
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